SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

Data Sheet (Cat.No.T4928)

TargetMol

L-Kynurenine

Chemical Properties



CAS No. : 2922-83-0

Formula: C10H12N2O3

Molecular Weight: 208.21

Appearance: no data available

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Biological Description

Description	L-Kynurenine ((S)-Kynurenine) is a key intermediate in the breakdown pathway of tryptophan. L-Kynurenine is a substrate of kynureninase, KMO, and KAT associated with the suppression of antitumor immune responses. It has been shown to inhibit allogeneic T-cell proliferation and to increase malignant U87 glioma cell invasion into a collagen matrix.
Targets(IC50)	AhR,Aryl Hydrocarbon Receptor,Endogenous Metabolite
In vitro	Kynurenine and its further breakdown products carry out diverse biological functions, including dilating blood vessels during inflammation and regulating the immune response. Some cancers increase kynurenine production thereby increasing tumor growth. L-kynurenine (Kyn) is an aryl hydrocarbon receptor (AHR) agonist that activates AHR-directed, naive T cell polarization to the anti-inflammatory Treg phenotype. Kynurenine activates AHR signaling at physiological concentrations in H1L7.5c3 cells and acts as an AHR agonist after a 24-hr exposure by inducing the AHR-regulated luciferase gene in H1L7.5c3 mouse hepatocyte cells.
In vivo	Kynurenine expands rat and human arteries by activating Kv7 channels in the vascular smooth muscle, a process that leads to rat hypotension, partially reversible by inhibiting these channels. When L-kynurenine is given one hour before hypoxia-ischemia, it significantly prevents neurological damage in a dose-dependent manner, achieving full protection at 300 mg/kg. Additionally, this dosage inhibits the activation of c-fos in the cerebral cortex.

Solubility Information

Solubility	DMSO: 50 mg/mL (240.14 mM),Sonication is recommended. 0.5M HCL: 50 mg/mL, H2O: 4 mg/mL (at 20°C), (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	4.8028 mL	24.0142 mL	48.0284 mL
5 mM	0.9606 mL	4.8028 mL	9.6057 mL
10 mM	0.4803 mL	2.4014 mL	4.8028 mL
50 mM	0.0961 mL	0.4803 mL	0.9606 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Kolho K L , Pessia A , Jaakkola T , et al. Faecal and serum metabolomics in paediatric inflammatory bowel disease [J]. Journal of Crohns & Colitis, 2017, 11(3):321-334.
Fukushima T , Iizuka H , Yokota A , et al. Quantitative